Rubbish Check
Daily Mail Money · 1 November 2026
source“AstraZeneca chief Pascal Soriot eyes record £28m pay package bonanza”
R3/ 10
Lightly altered
Rubbish Rating — 1 = base fact, 10 = pure rubbish
12345678910
In short
Rubbish Talk rates the Daily Mail's claim that AstraZeneca's Pascal Soriot is "eyeing" a record £28m pay package a 3/10, because the figure is an accurately-described maximum ceiling under a plan still being drafted, but the headline's "bonanza" framing buries AstraZeneca's own denial that it's "inaccurate to speculate" on the number.
The Verdict
Lightly altered. The core numbers check out and "eyes" correctly signals this is a target, not a done deal, but the loaded word "bonanza" and the company's on-the-record pushback, relegated to the final line of the story, tilt the framing toward sensational rather than neutral.
What actually happened
AstraZeneca is consulting shareholders on a new three-year pay policy that could raise CEO Pascal Soriot's maximum potential pay to £28million, up from a current maximum of £19.6million this year. The plan is not finalised, and a company spokesperson told the Mail it was "inaccurate to speculate on any future potential executive remuneration as the next three-year pay policy is still being drafted."
Key facts
- Soriot received £17.7million last year, already the highest pay packet of any FTSE 100 chief executive.
- His maximum potential pay this year is £19.6million if all targets are hit, below the average for global pharma peers, according to AstraZeneca.
- The new proposal under discussion would raise his ceiling to a record £28million.
- His long-term incentive plan already paid him £11.6million last year and is worth up to 850% of his £1.6million salary, with scope to rise further; his bonus cap (currently 300% of salary) is also set to rise.
- AstraZeneca's pay committee chair Sheri McCoy has stated the company wants to "close this gap" with global peers over time.
- The same Fat Cat Files review flags Shell, Rolls-Royce and Unilever bosses as also able to clear £20million-plus under similar maximum-target scenarios, suggesting this is a sector-wide pattern, not an AstraZeneca-specific outlier.
What to watch for
- Whether the £28million figure survives into the formal remuneration policy put to a binding shareholder vote at next year's AGM, since proxy advisers ISS and Glass Lewis have historically opposed Soriot's pay rises as "excessive."
- Whether Soriot's actual realised pay tracks close to the new maximum, as it has in recent years (£17.7m actual against a slightly higher ceiling), which would validate the headline figure as a realistic outcome rather than a worst-case scare number.
About this scoreThe R-Score is Rubbish Talk's editorial opinion on how far a headline's framing sits from what the underlying facts support. It is a judgement about presentation and emphasis, not an allegation that any outlet has acted dishonestly. Every figure we rely on is linked under Receipts so you can check it yourself.
